C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 403/04 (2006.01) A61K 31/40 (2006.01) A61K 31/404 (2006.01) A61K 31/415 (2006.01) A61K 31/416 (2006.01) A61K 31/42 (2006.01) A61K 31/422 (2006.01) A61K 31/425 (2006.01) A61K 31/44 (2006.01) A61K 31/4439 (2006.01) A61K 31/47 (2006.01) A61K 31/4709 (2006.01) A61K 31/495 (2006.01) A61K 31/50 (2006.01) A61K 31/505 (2006.01) A61K 31/506 (2006.01) A61K 31/535 (2006.01) A61K 31/5377 (2006.01) A61P 25/00 (2006.01) A61P 25/22 (2006.01) A61P 25/24 (2006.01) A61P 43/00 (2006.01) C07D 209/02 (2006.01) C07D 209/40
Patent
CA 2438582
This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and apharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.
Cette invention concerne des dérivés de pyrimidine et d'indolone lesquels sont des antagonistes sélectifs du récepteur GAL3. L'invention concerne une composition pharmaceutique contenant une dose thérapeutique efficace d'un composé de l'invention et un excipient pharmaceutiquement acceptable. Cette invention concerne également une composition pharmaceutique obtenue par combinaison d'une dose thérapeutique efficace d'un composé de l'invention et d'un excipient pharmaceutiquement acceptable. Cette invention concerne aussi un procédé de production d'une composition pharmaceutique consistant à combiner une dose thérapeutique efficace d'un composé de l'invention et d'un excipient pharmaceutiquement acceptable. De plus, l'invention concerne une méthode de traitement d'un sujet souffrant de dépression et/ou d'anxiété consistant à administrer à ce dernier une dose d'un composé de l'invention efficace pour traiter la dépression et/ou l'anxiété du sujet. En outre, cette invention concerne une méthode de traitement de la dépression et/ou de l'anxiété chez un sujet consistant à lui administrer une composition contenant un excipient pharmaceutiquement acceptable ainsi qu'une dose thérapeutique efficace d'un antagoniste du récepteur GAL3.
Blackburn Thomas P.
Boteju Lakmal
Chen Heidi
Jimenez Hermo
Konkel Michael J.
H. Lundbeck A/s
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Synaptic Pharmaceutical Corporation
LandOfFree
Use of gal3 receptor antagonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of gal3 receptor antagonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of gal3 receptor antagonists for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1512199